secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001493152-23-020595
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Q1 revenue up 6% to $3.9M; operating expenses cut 20%; net loss narrows
-----------------------------------------------------------------------------

- Revenue $3.9M (+6% YoY); gross margin 61% vs 70% on higher VIP training costs.
- Operating expenses fell 20%; net loss reduced with $3.2M non-cash derivative gain.
- VIP enrollments 38 (+19% YoY); VIP revenue $1.3M (+42%). Cash $7.0M.
- Acquired AFD patents/TMD-Bruxism products; POD study showed 92% migraine resolution.
- Targeting positive cash flow in Q1 2024; multiple DSO/DME pilots underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/0001493152-23-020595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223020595/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-020595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer